Table 4.
Comparison between groups and development within groups with regard to the sum of scores within each of the three parts of the QLQ-C30 and QLQ-BR23
| Variable | Treatment | Screening | Day 16 | Day 32 | Screening – Day 32 |
|---|---|---|---|---|---|
| Physical activity problems | BP-C1 (n=15) |
8.0 (1.8) 7.0 to 9.0 |
7.4 (1.6) 6.5 to 8.3 |
8.2 (3.8) 6.1 to 10.3 |
−0.2 (3.3) −2.2 to 1.6 |
| Placebo (n=15) |
8.0 (2.5) 6.6 to 9.4 |
7.9 (2.3) 6.6 to 9.1 |
8.4 (3.8) 7.2 to 9.6 |
−0.4 (1.5) −1.2 to 0.4 |
|
| Discomfort last week | BP-C1 (n=15) |
35.3 (9.7) 29.9 to 40.7 |
33.6 (6.7) 29.9 to 37.3 |
35.9 (13.3) 28.5 to 43.2 |
−0.6 (6.2) −4.0 to 2.8 |
| Placebo (n=15) |
33.1 (10.3) 27.4 to 38.8 |
34.6 (7.7) 30.3 to 38.9 |
36.7 (8.5) 32.0 to 41.4 |
−3.5 (12.4) −10.4 to 3.3 |
|
| Health and life quality | BP-C1 (n=15) |
9.2 (2.7) 7.7 to 10.7 |
9.6 (1.7) 8.6 to 10.6 |
8.8 (3.0) 7.1 to 10.5 |
0.4 (2.1) −0.7 to 1.5 |
| Placebo (n=15) |
8.1 (2.6) 6.6 to 9.5 |
8.6 (2.4) 7.3 to 9.9 |
7.9 (2.2) 6.7 to 9.1 |
0.2 (2.7) −1.4 to 1.6 |
|
| BP-C1 treatment problems last week | BP-C1 (n=15) |
22.3 (4.9) 19.6 to 24.4 |
19.6 (3.7) 17.6 to 21.6 |
19.9 (5.8) 16.7 to 23.1 |
2.4 (4.1) 0.1 to 4.7 |
| Placebo (n=15) |
20.9 (4.8) 18.2 to 23.5 |
19.6 (4.2) 17.3 to 21.9 |
19.5 (4.1) 17.3 to 21.8 |
1.3 (4.4) −1.1 to 3.8 |
|
| Sexual interest and activity, last 4 weeks | BP-C1 (n=15) |
2.8 (1.0) 2.2 to 3.4 |
3.1 (1.4) 2.4 to 3.9 |
3.1 (2.3) 1.8 to 4.3 |
−0.3 (2.1) −1.4 to 0.9 |
| Placebo (n=15) |
3.3 (1.9) 2.2 to 4.3 |
2.9 (1.9) 1.9 to 4.0 |
3.0 (1.8) 2.0 to 4.0 |
0.3 (2.2) −0.9 to 1.5 |
|
| BC-related pain and discomfort last week | BP-C1 (n=15) |
11.1 (4.8) 8.4 to 13.7 |
10.4 (4.5) 7.7 to 13.0 |
9.8 (3.8) 7.6 to 12.0 |
1.4 (2.3) 0.04 to 2.7 |
| Placebo (n=15) |
10.1 (3.4) 8.2 to 12.0 |
10.2 (2.7) 8.7 to 11.7 |
10.3 (2.5) 8.9 to 11.7 |
−0.2 (3.1) −1.9 to 1.5 |
Note: Results are expressed as mean (standard deviation) and 95% confidence intervals.
Abbreviations: BC, breast cancer; BP-C1, benzene-poly-carboxylic acids complex with cis-diammineplatium (II) dichloride; QLQ-BR23, European Organisation for Research and Treatment of Cancer quality of life breast-cancer–specific questionnaire; QLQ-C30, European Organisation for Research and Treatment of Cancer quality of life questionnaire.